Our Vision
invoX’s vision is to be a leading developer, manufacturer and supplier of complex respiratory drug-device combination and medicinal products to patients.
The Global Burden of Respiratory Diseases
Respiratory diseases are a leading cause of illness and death worldwide. The prevalence of chronic respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD), continues to rise, placing an increasing burden on public health systems and significantly impacting patients’ quality of life.
Other disease areas requiring effective inhaled therapy include Pulmonary Hypertension (PAH), Idiopathic Pulmonary Fibrosis (IPF) and Cystic Fibrosis (CF); these areas are currently center of our research focus.
Despite significant advances in the development of inhaled therapeutics for these and other respiratory conditions, there remains a growing unmet need for innovative treatments, as well as high-quality, affordable versions of established inhaled products with proven safety and efficacy. Our dedicated respiratory team is passionate about addressing these needs and committed to delivering effective solutions for patients.
Softhaler®, Soft-Mist Inhaler technology
Our respiratory team has developed a next-generation, proprietary soft-mist inhalation platform device, the Softhaler®, which uses differentiated technology to deliver propellant-free liquid-based formulations to the lung. This device has been developed to enable platform flexibility and adaptability to individual patient, indication and medication needs.
Our technology has a better sustainability footprint than traditional inhalers due to simpler, typically water-based formulations which require a less intensive manufacturing process and contain no propellants or other volatile chemicals of environmental concern.